ArticleDrug delivery2021
Novel optimized drug delivery systems for enhancing spinal cord injury repair in rats.
Article in Drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Polysaccharide-Based Hydrogel Composites With Organic and Inorganic Fillers: Recent Advances in Reinforcement, Functional Properties, and Selected Applications.ChemSusChem · 2026Review
- Nanoformulated fingolimod attenuates NLRP3 inflammasome activation and promotes functional recovery in a rat model of spinal cord injury.Spinal cord · 2026Article
- Harnessing spatiotemporal melatonin delivery from engineered platforms for targeted microenvironment remodeling in peripheral neuropathy.Materials today. Bio · 2026Review
- Fostering Regeneration and Functional Improvement in the Injured Spinal Cord by a Novel, Stem Cell Secretome-Based Drug Delivery Method.Pharmaceutics · 2026Article
- Regulation of microglial polarization via notch signaling pathway by intrathecal administration of tanshinone IIA-PLGA sustained-release microspheres to promote neurological recovery after spinal cord injury.Frontiers in bioengineering and biotechnology · 2026Article
- Uric Acid Released from Poly (Lactic-co-Glycolic Acid) Nanoparticles Mitigates Glutamate-Induced Excitotoxicity of Spinal Cord Neurons.ASN neuro · 2026Article
- Hydrogel Microspheres for Biomedical Applications.Small science · 2026Review
- miR-365 promotes HOXA9-mediated differentiation of mesenchymal stem cells to nucleus pulposus cells by interacting with HIF-1α.World journal of orthopedics · 2025Article
- Multidimensional exploration of hydrogels as biological scaffolds for spinal cord regeneration: mechanisms and future perspectives.Frontiers in bioengineering and biotechnology · 2025Review
- Effect of melatonin loaded chitosan hydrogel on rat spinal cord injury.Veterinary research forum : an international quarterly journal · 2025Article
- Review
- Advancements and Applications of Injectable Hydrogel Composites in Biomedical Research and Therapy.Gels (Basel, Switzerland) · 2023Review
- Hydrogel scaffolds in the treatment of spinal cord injury: a review.Frontiers in neuroscience · 2023Review
- Melatonin, a natural antioxidant therapy in spinal cord injury.Frontiers in cell and developmental biology · 2023Review
- Intestinal microbiota and melatonin in the treatment of secondary injury and complications after spinal cord injury.Frontiers in neuroscience · 2022Review
- Biomaterials delivery strategies to repair spinal cord injury by modulating macrophage phenotypes.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective and accurate delivery of drugs to tissue with spinal cord injury (SCI) is the key to rehabilitating neurological deficits. Sustained-release microspheres (MS) have excellent degradability and can aid in the long-term release of drugs. However, the burst release phenomenon can cause unexpected side effects. Herein, we developed and optimized an injectable poly(lactic-co-glycolic acid) (PLGA) MS loaded with melatonin(Mel), which were mixed further with Laponite hydrogels (Lap/MS@Mel, a micro-gel compound) in order to reduce the burst release of MS. Thus, these MS were able to achieve stable and prolonged Mel release, as well as synergistic Lap hydrogel in order to repair neural function in SCI by in situ injection. In clinical practice, patients with SCI have complicated conditions and significant inter-individual differences, which means that a single route of administration does not meet actual clinical needs. Thus, the nanospheres are synthesized and subsequently coated with platelet membrane (PM) in order to form PM/MS@Mel (nano-PM compound) for sustained and precision-targeted delivery of Mel intravenously in the SCI. Notably, optimized microsphere delivery systems have improved Mel regulation polarization of spinal microglial/macrophages, which can reduce loss of biomaterials due to macrophage-induced immune response during implantation of spinal cord tissue. These two new delivery systems that are based on MS provide references for the clinical treatment of SCI, according to different requirements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.